Table 1 Baseline characteristics by use or not of Remdesivir, after the matching using a propensity score.
Parameter | Controls (n = 365) | Remdesivir (n = 365) | p-value |
|---|---|---|---|
Demographics | |||
Age (mean, SD) | 55.4 (15.0) | 56.2 (17.1) | 0.52 |
Females (%) | 59.7 | 52.6 | 0.06 |
Current smokers (%) | 9.3 | 3.0 | < 0.0001 |
Comorbidities | |||
Any comorbidity | 47.1 | 52.1 | 0.21 |
Hypertension | 48.8 | 40.3 | 0.03 |
Dyslipidemia | 20.5 | 26.6 | 0.07 |
Type 2 diabetes | 20.8 | 14.2 | 0.03 |
Obesity | 16.4 | 9.0 | 0.005 |
COVID-19 clinics | |||
Dyspnea | 36.7 | 28.5 | 0.02 |
Anosmia | 4.9 | 6.6 | 0.43 |
Dysgeusia | 18.1 | 28.5 | 0.001 |
Fever | 58.9 | 76.2 | < 0.0001 |
Cough | 34.2 | 41.4 | 0.06 |
Gastrointestinal symptoms (%) | 14.8 | 20.5 | 0.05 |
SpO2 < 92% | 71.0 | 71.0 | 1.00 |
Presence of pneumonia | 93.2 | 94.0 | 0.76 |
Vaccinated against COVID-19 (%) | 62.5 | 24.9 | < 0.0001 |
Other therapies | |||
Use of corticosteroids | 72.6 | 81.6 | 0.05 |
Use of heparins | 80.0 | 81.6 | 0.64 |
Use of monoclonal antibodies | 8.9 | 11.8 | 0.25 |
